Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Acorda Therapeutics Inc    ACOR

ACORDA THERAPEUTICS INC (ACOR)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
04/16/2018 04/17/2018 04/18/2018 04/19/2018 04/20/2018 Date
23.35(c) 23.9(c) 23.9(c) 23.4(c) 23.35(c) Last
161 579 294 686 313 303 240 508 204 620 Volume
0.00% +2.36% 0.00% -2.09% -0.21% Change
More quotes
Financials (USD)
Sales 2018 370 M
EBIT 2018 23,2 M
Net income 2018 -44,6 M
Debt 2018 274 M
Yield 2018 -
Sales 2019 150 M
EBIT 2019 -92,3 M
Net income 2019 -171 M
Debt 2019 127 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 3,70x
EV / Sales2019 8,14x
Capitalization 1 095 M
More Financials
Company
Acorda Therapeutics, Inc. develops and markets therapeutic products for nervous system disorders.The company's two main products are Ampyra and Zanaflex Capsules.The Ampyra is an oral drug, which treats to improve walking in patients with multiple sclerosis and Zanaflex Capsules, which is a short... 
Sector
Biotechnology & Medical Research
Calendar
04/23 | 08:30pmPresentation
More about the company
Surperformance© ratings of Acorda Therapeutics Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on ACORDA THERAPEUTICS INC
04/16ACORDA THERAPEUTICS : to Present New Data For INBRIJA™ (levodopa inhalatio..
BU
04/11ACORDA FIRST QUARTER UPDATE : Webcast/Conference Call Scheduled for May 2, 2018
BU
03/26ACORDA THERAPEUTICS,INC. (NASDAQ : ACOR) Files An 8-K Other Events
AQ
03/26ACORDA THERAPEUTICS INC : Other Events, Financial Statements and Exhibits (form ..
AQ
03/22ACORDA THERAPEUTICS : to Present at Oppenheimer Healthcare Conference
AQ
03/19ACORDA THERAPEUTICS : 420 Saw Mill River Rd. Ardsley, NY 10502
AQ
03/19ACORDA THERAPEUTICS : 65-- Acorda Therapeutics, Inc. 420 Saw Mill River Rd. Ards..
AQ
03/17ACORDA THERAPEUTICS : $97.35 Million Federal Contract Awarded to Acorda Therapeu..
AQ
03/15ACORDA THERAPEUTICS : to Present at Cowen Health Care Conference
AQ
03/14ACORDA THERAPEUTICS : Rallies Parkinson’s Community in First-of-Its-Kind I..
BU
More news
Sector news : Bio Therapeutic Drugs
04/19Novartis CEO feels heat on U.S. generics, Cosentyx drop
RE
04/17GE rides gene therapy wave with ready-made viral drug factories
RE
04/12GSK slims portfolio with sale of rare disease gene therapy drugs
RE
04/12UK gene therapy firm Orchard plans stock offer after GSK deal
RE
04/12TAKEDA SOUNDS OUT BANKS FOR LOANS AS : sources
RE
More sector news : Bio Therapeutic Drugs
Latest Tweets
04/20Zacks Investment Research Lowers Acorda Therapeutics $ACOR to Strong Sell  
04/16$ACOR Acorda - Acorda to Present New Data For INBRIJA™ (levodopa inhalation p.. 
04/11$ACOR Acorda - Acorda Provides Financial and Pipeline Update for First Quarte.. 
04/11$ACOR Acorda - Acorda First Quarter Update: Webcast/Conference Call Scheduled.. 
04/09$125.73 Million in Sales Expected for Acorda Therapeutics Inc $ACOR This Quar.. 
More tweets
Qtime:150
News from SeekingAlpha
04/19INSTITUTIONAL TOP IDEAS SERIES : Scopia Capital 
03/29Looking For Action? S&P 1500 Most Volatile Stocks 
03/26Acorda files marketing application in Europe for Parkinson's med Inbrija; sha.. 
03/16Key events next week - healthcare (continued #1) 
03/09Key events next week - healthcare (continued #3) 
Chart ACORDA THERAPEUTICS INC
Duration : Period :
Acorda Therapeutics Inc Technical Analysis Chart | ACOR | US00484M1062 | 4-Traders
Technical analysis trends ACORDA THERAPEUTICS INC
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 9
Average target price 25,5 $
Spread / Average Target 9,2%
EPS Revisions
Managers
NameTitle
Ronald Cohen President, Chief Executive Officer & Director
Andrew R. Blight Chief Scientific Officer
Richard P. Batycky Chief Technology Officer
Burkhard Blank Chief Medical Officer
Sandra Panem Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ACORDA THERAPEUTICS INC9.09%1 095
GILEAD SCIENCES3.91%96 094
VERTEX PHARMACEUTICALS6.47%40 153
REGENERON PHARMACEUTICALS-15.99%33 844
GENMAB23.13%12 812
BEIGENE LTD (ADR)71.91%8 998